Tanishima Hiroyuki, Horiuchi Tetsuya, Tamagawa Koji, Tsujimoto Takehiro, Miyagawa Yoshimasa, Ishida Koichiro, Uemura Ryuichiro, Hama Takashi, Sakaguchi Satoru, Shono Yoshiharu, Tsubakihara Hideaki, Tabuse Katsuyoshi
Department of Surgery, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan.
Gan To Kagaku Ryoho. 2010 Jul;37(7):1397-400.
In patients with advanced rectal cancer, preoperative chemoradiotherapy is superior to postoperative chemoradiotherapy because of causing less toxicity and achieving higher rates of sphincter preservation and curative resection. We treated a patient who had advanced rectal cancer with preoperative chemotherapy using S-1 and concurrent radiotherapy. S-1 was orally administered at a dose of 100 mg/day during the first cycle (two-week on and one week off). During the third cycle, radiotherapy was initiated concurrently and a total dose of 45 Gy was given. The most severe adverse event was grade 3 leukopenia during the third cycle. On day 42 after completing radiotherapy, low anterior resection with diverting colostomy was performed. Histological examination found no viable cancer cells in the resected specimens, including the primary tumor site and lymph nodes. Thus, a pathological complete response was achieved. Postoperatively, anastomotic leakage occurred, but it was resolved with transanal drainage. Preoperative chemoradiotherapy using S-1 contributed to sphincter preservation and curative resection in this patient. This regimen was both effective and well-tolerated, suggesting that it could be useful for advanced rectal cancer.
在晚期直肠癌患者中,术前放化疗优于术后放化疗,因为其毒性较小,括约肌保留率和根治性切除率更高。我们治疗了一名晚期直肠癌患者,采用S-1进行术前化疗并同步放疗。S-1在第一个周期以100 mg/天的剂量口服给药(两周用药,一周停药)。在第三个周期,同步开始放疗,总剂量为45 Gy。最严重的不良事件是第三个周期出现3级白细胞减少。放疗结束后第42天,进行了低位前切除术并加做转流性结肠造口术。组织学检查发现切除标本中没有存活的癌细胞,包括原发肿瘤部位和淋巴结。因此,实现了病理完全缓解。术后发生了吻合口漏,但通过经肛门引流得以解决。使用S-1进行术前放化疗有助于该患者保留括约肌并实现根治性切除。该方案既有效又耐受性良好,表明其可能对晚期直肠癌有用。